［1］ BILLER LH,SCHRAG D.Diagnosis and treatment of metastatic colorectal cancer:A review［J］.JAMA,2021,325(7):669-685.
［2］ QIU H,CAO S,XU R.Cancer incidence,mortality,and burden in China:a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020［J］.Cancer Commun (Lond),2021,41(10):1037-1048.
［3］ KOTANI D,OKI E,NAKAMURA Y,et al.Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer［J］.Nat Med,2023,29(1):127-134.
［4］ LOUPAKIS F,SHARMA S,DEROUAZI M,et al.Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases［J］.JCO Precis Oncol,2021,5:1166-1177.
［5］ NIKANJAM M,KATO S,KURZROCK R.Liquid biopsy:current technology and clinical applications［J］.J Hematol Oncol,2022,15(1):131.
［6］ LARSON MH,PAN W,KIM HJ,et al.A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection［J］.Nat Commun,2021,12(1):2357.
［7］ DRAG MH,KILPELAINEN TO.Cell-free DNA and RNA-measurement and applications in clinical diagnostics with focus on metabolic disorders［J］.Physiol Genomics,2021,53(1):33-46.
［8］ HASSAN S,SHEHZAD A,KHAN SA,et al.Diagnostic and therapeutic potential of circulating-free DNA and cell-free RNA in cancer management［J］.Biomedicines,2022,10(8):2047.
［9］ CHEUNG K,CHOI SR,LEE L,et al.The potential of circulating cell free RNA as a biomarker in cancer［J］.Expert Rev Mol Diagn,2019,19(7):579-590.
［10］ RAEZ LE,DANENBERG K,SUMARRIVA D,et al.Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors［J］.Cancer Drug Resist,2021,4(4):1061-1071.
［11］ JIN N,KAN CM,PEI XM,et al.Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer［J］.Front Oncol,2023,13:1134445.
［12］ EKINE-AFOLABI BA,NJAN AA,ROTIMI SO,et al.The impact of diet on the involvement of non-coding RNAs,extracellular vesicles,and gut microbiome-virome in colorectal cancer initiation and progression［J］.Front Oncol,2020,10:583372.
［13］ CHOI EJ,KIM YJ.Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma［J］.J Liver Cancer,2022,22(2):103-114.
［14］ GAO Y,WANG H,CHEN S,et al.Single-cell N(6)-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy［J］.J Transl Med,2022,20(1):197.
［15］ DEBATTISTA J,GRECH L,SCERRI C,et al.Copy number variations as determinants of colorectal tumor progression in liquid biopsies［J］.Int J Mol Sci,2023,24(2):1738.
［16］ BOUSSIOS S,OZTURK MA,MOSCHETTA M,et al.The developing story of predictive biomarkers in colorectal cancer［J］.J Pers Med,2019,9(1):12.
［17］ ZHANG W,HU X,JIANG Z.Small extracellular vesicles:key forces mediating the development and metastasis of colorectal cancer［J］.Cells,2022,11(11):1780.
［18］ YAMAMOTO Y,KASASHIMA H,FUKUI Y,et al.The heterogeneity of cancer-associated fibroblast subpopulations:Their origins,biomarkers,and roles in the tumor microenvironment［J］.Cancer Sci,2023,114(1):16-24.
［19］ RAEZ LE,DANENBERG K,SUMARRIVA D,et al.Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors［J］.Cancer Drug Resist,2021,4(4):1061-1071.
［20］ XUE VW,CHEUNG MT,CHAN PT,et al.Non-invasive potential circulating mRNA markers for colorectal adenoma using targeted sequencing［J］.Sci Rep,2019,9(1):12943.
［21］ NASSAR FJ,MSHEIK ZS,ITANI MM,et al.Circulating miRNA as biomarkers for colorectal cancer diagnosis and liver metastasis［J］.Diagnostics (Basel),2021,11(2):341.
［22］ FELLIZAR A,REFUERZO V,RAMOS JD,et al.Expression of specific microRNAs in tissue and plasma in colorectal cancer［J］.J Pathol Transl Med,2023,57(3):147-157.
［23］ SILVA C,BARROS-FILHO MC,WONG D,et al.Circulating let-7e-5p,miR-106a-5p,miR-28-3p,and miR-542-5p as a promising microRNA signature for the detection of colorectal cancer［J］.Cancers (Basel),2021,13(7):1493.
［24］ ABO-ELELA DA,SALEM AM,SWELLAM M,et al.Potential diagnostic role of circulating MiRNAs in colorectal cancer［J］.Int J Immunopathol Pharmacol,2023,37:1190364661.
［25］ POURSHEIKHANI A,ABBASZADEGAN MR,KERACHIAN MA.Mechanisms of long non-coding RNA function in colorectal cancer tumorigenesis［J］.Asia Pac J Clin Oncol,2021,17(1):7-23.
［26］ SOLE C,ARNAIZ E,MANTEROLA L,et al.The circulating transcriptome as a source of cancer liquid biopsy biomarkers［J］.Semin Cancer Biol,2019,58:100-108.
［27］ ABEDINI P,FATTAHI A,AGAH S,et al.Expression analysis of circulating plasma long noncoding RNAs in colorectal cancer:The relevance of lncRNAs ATB and CCAT1 as potential clinical hallmarks［J］.J Cell Physiol,2019,234(12):22028-22033.
［28］ RADANOVA M,MIHAYLOVA G,TASINOV O,et al.New circulating circular RNAs with diagnostic and prognostic potential in advanced colorectal cancer［J］.Int J Mol Sci,2021,22(24):13283.
［29］ PU XX,HUANG GL,GUO HQ,et al.Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression［J］.J Gastroenterol Hepatol,2010,25(10):1674-1680.
［30］ PUN JC,CHAN JY,CHUN BK,et al.Plasma Bmi1 mRNA as a potential prognostic biomarker for distant metastasis in colorectal cancer patients［J］.Mol Clin Oncol,2014,2(5):817-820.
［31］ CUI C,ZHANG R,GU F,et al.Plasma CXCL3 levels are associated with tumor progression and an unfavorable colorectal cancer prognosis［J］.J Immunol Res,2022,2022:1336509.
［32］ KUDELOVA E,HOLUBEKOVA V,GRENDAR M,et al.Circulating miRNA expression over the course of colorectal cancer treatment［J］.Oncol Lett,2022,23(1):18.
［33］ HAO YJ,YANG CY,CHEN MH,et al.Potential values of circulating microRNA-21 to predict early recurrence in patients with colorectal cancer after treatments［J］.J Clin Med,2022,11(9):2400.
［34］ ANGERILLI V,GALUPPINI F,BUSINELLO G,et al.MicroRNAs as predictive biomarkers of resistance to targeted therapies in gastrointestinal tumors［J］.Biomedicines,2021,9(3):318.
［35］ 赵婷婷,张清媛.PD-1/PD-L1介导的肿瘤免疫逃逸在肿瘤微环境中的研究进展［J］.现代肿瘤医学,2021,29(03):520-523.
ZHAO Tingting,ZHANG Qingyuan.Advances in research of PD-1/PD-L1 mediated tumor immune escape in tumor microenvironment［J］.Modern Oncology,2021,29(03):520-523.
［36］ CHEN Q,XIA HW,GE XJ,et al.Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases［J］.Asian Pac J Cancer Prev,2013,14(12):7421-7426.
［37］ KJERSEM JB,IKDAHL T,LINGJAERDE OC,et al.Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment［J］.Mol Oncol,2014,8(1):59-67.
［38］ HU J,CAI G,XU Y,et al.The plasma microRNA miR-1914* and -1915 suppresses chemoresistant in colorectal cancer patients by down-regulating NFIX［J］.Curr Mol Med,2016,16(1):70-82.
［39］ GE T,XIANG P,MAO H,et al.Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1［J］.Exp Ther Med,2020,20(3):2134-2140.
［40］ ZHANG J,ZHANG K,BI M,et al.Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy［J］.Anticancer Drugs,2014,25(3):346-352.
［41］ YE D,LIU H,ZHAO G,et al.LncGMDS-AS1 promotes the tumorigenesis of colorectal cancer through HuR-STAT3/Wnt axis［J］.Cell Death Dis,2023,14(2):165.
［42］ TORO PV,ERLANGER B,BEAVER JA,et al.Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA［J］.Clin Biochem,2015,48(15):993-998.
［43］ KIRSCHNER MB,EDELMAN JJ,KAO SC,et al.The impact of hemolysis on cell-free microRNA biomarkers［J］.Front Genet,2013,4:94.
［44］ OZSOLAK F,MILOS PM.RNA sequencing:advances,challenges and opportunities［J］.Nat Rev Genet,2011,12(2):87-98.
［45］ HOLCAR M,KANDUSER M,LENASSI M.Blood nanoparticles-influence on extracellular vesicle isolation and characterization［J］.Front Pharmacol,2021,12:773844.
［46］ WOLFIEN M,RIMMBACH C,SCHMITZ U,et al.TRAPLINE:a standardized and automated pipeline for RNA sequencing data analysis,evaluation and annotation［J］.BMC Bioinformatics,2016,17:21.
［47］ JIANG P,LO Y.Enhanced cancer detection from cell-free DNA［J］.Nat Biotechnol,2022,40(4):473-474.
［48］ DING SC,LO Y.Cell-free DNA fragmentomics in liquid biopsy［J］.Diagnostics (Basel),2022,12(4):978.